Refine
Year of publication
Document Type
- Article (51)
Language
- English (51)
Has Fulltext
- yes (51)
Is part of the Bibliography
- no (51)
Keywords
- integrins (8)
- prostate cancer (7)
- bladder cancer (6)
- growth (6)
- proliferation (6)
- adhesion (5)
- invasion (5)
- renal cell carcinoma (5)
- sulforaphane (5)
- HDAC (4)
- curcumin (4)
- mTOR (3)
- renal cell cancer (3)
- resistance (3)
- valproic acid (3)
- Adhesion (2)
- CD44 (2)
- Diagnosis (2)
- HCMV (2)
- cabozantinib (2)
- chemotaxis (2)
- prostate carcinoma cells (2)
- resistant cell lines (2)
- temsirolimus (2)
- tumor growth (2)
- AKT-mTOR pathway (1)
- Akt-mTOR pathway (1)
- Akt-mTOR signaling (1)
- Antioxidant (1)
- Antiproliferative (1)
- Benign prostatic hyperplasia (1)
- Biological markers (1)
- Biomarker (1)
- CDK-cyclin axis (1)
- CXCL12 (1)
- CXCR4 (1)
- Chemokine CCL2 (1)
- Chemokines (1)
- Chemoprevention (1)
- Curcumis sativus (1)
- Dietary HDAC inhibitor (1)
- Everolimus resistance (1)
- HDAC-inhibition (1)
- HUVEC (1)
- IGF-1 (1)
- ITGA7 (1)
- Keap1-Nrf2 (1)
- N-myc (1)
- NCAM (1)
- Prediction (1)
- Prostate cancer (1)
- Prostatic neoplasms (1)
- Pumpkin seeds (1)
- ROS (1)
- Renal cell carcinoma (1)
- Sulphoraphane (1)
- TLR7 (1)
- TLR8 (1)
- Tumor growth (1)
- Urologic tumors (1)
- VPA-analogues (1)
- agonists (1)
- amygdalin (1)
- beta1 integrins (1)
- bioavailability (1)
- c-MET (1)
- cabazitaxel (1)
- cdk (1)
- cdk2/cyclin A (1)
- cell cycling (1)
- cell growth (1)
- chemoprotection (1)
- chemoresistance (1)
- complementary and alternative medicine (1)
- complementary/alternative medicine (CAM) (1)
- cross-communication (1)
- cyclins (1)
- docetaxel (1)
- drug resistance (1)
- endothelial cells (1)
- endothelial receptor expression (1)
- everolimus (1)
- hepatocellular carcinoma (1)
- histone deacetylase (1)
- immune (1)
- inflammation (1)
- leukocytes (1)
- light irradiation (1)
- marker (1)
- mechanistic target of rapamycin (mTOR) (1)
- membrane fragments (1)
- metastasis (1)
- mtor (1)
- olive mill wastewater (OMWW) (1)
- oncomodulation (1)
- oxidative stress (1)
- p73 (1)
- pancreatic cancer (1)
- penile cancer (1)
- programmed cell death ligand 1 (1)
- programmed cell death protein 1 (1)
- prostate cancer cells (1)
- sE-cadherin (1)
- second-line (1)
- signalling proteins (1)
- squamous cell carcinoma (1)
- targeted therapy (1)
- temsirolimus-resistance (1)
- testicular cancer (1)
- tivantinib (1)
- tumor adhesion (1)
- tumor dissemination (1)
- tumor immune escape (1)
- tumor migration (1)
- tumor proliferation (1)
- tumour growth (1)
- tyrosine kinase inhibitors (1)
- vascular endothelial growth factor receptor 2 (1)
Institute
- Medizin (49)
- Biowissenschaften (3)
- Biochemie, Chemie und Pharmazie (1)
Insulin-like growth factor-1 (IGF-1)-related signaling is associated with prostate cancer progression. Links were explored between IGF-1 and expression of integrin adhesion receptors to evaluate relevance for growth and migration. Androgen-resistant PC3 and DU145 and androgen-sensitive LNCaP and VCaP prostate cancer cells were stimulated with IGF-1 and tumor growth (all cell lines), adhesion and chemotaxis (PC3, DU145) were determined. Evaluation of Akt/mTOR-related proteins, focal adhesion kinase (FAK) and integrin α and β subtype expression followed. Akt knock-down was used to investigate its influence on integrin expression, while FAK blockade served to evaluate its influence on mTOR signaling. Integrin knock-down served to investigate its influence on tumor growth and chemotaxis. Stimulation with IGF-1 activated growth in PC3, DU145, and VCaP cells, and altered adhesion and chemotactic properties of DU145 and PC3 cells. This was associated with time-dependent alterations of the integrins α3, α5, αV, and β1, FAK phosphorylation and Akt/mTOR signaling. Integrin blockade or integrin knock-down in DU145 and PC3 cells altered tumor growth, adhesion, and chemotaxis. Akt knock-down (DU145 cells) cancelled the effect of IGF-1 on α3, α5, and αV integrins, whereas FAK blockade cancelled the effect of IGF-1 on mTOR signaling (DU145 cells). Prostate cancer growth and invasion are thus controlled by a fine-tuned network between IGF-1 driven integrin-FAK signaling and the Akt-mTOR pathway. Concerted targeting of integrin subtypes along with Akt-mTOR signaling could, therefore, open options to prevent progressive dissemination of prostate cancer.